Indaptus Therapeutics Inc (INDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has a cash flow conversion efficiency ratio of -0.663x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($4.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Indaptus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Indaptus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Indaptus Therapeutics Inc for a breakdown of total debt and financial obligations.
Indaptus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indaptus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euroespes S.A.
MC:EEP
|
0.003x |
|
CodeLab Capital A/S
OL:CODE
|
N/A |
|
Codrus Minerals Ltd
AU:CDR
|
-0.465x |
|
Cre8 Enterprise Limited Class A Ordinary Shares
NASDAQ:CRE
|
0.155x |
|
International Lithium Corp
V:ILC
|
-0.028x |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
0.015x |
|
Jet.AI Inc.
NASDAQ:JTAI
|
0.031x |
|
Sherpa II Holdings Corp
V:SHRP
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Indaptus Therapeutics Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see INDP market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.94 Million | $-12.32 Million | -3.124x | -181.42% |
| 2023-12-31 | $12.08 Million | $-13.41 Million | -1.110x | -109.05% |
| 2022-12-31 | $24.63 Million | $-13.08 Million | -0.531x | -68.83% |
| 2021-12-31 | $35.90 Million | $-11.29 Million | -0.315x | -102.25% |
| 2020-12-31 | $-237.70K | $-3.32 Million | 13.987x | +655.47% |
| 2019-12-31 | $11.54 Million | $-29.05 Million | -2.518x | -245.03% |
| 2018-12-31 | $53.55 Million | $-39.08 Million | -0.730x | -93.89% |
| 2017-12-31 | $58.80 Million | $-22.13 Million | -0.376x | +28.82% |
| 2016-12-31 | $22.70 Million | $-12.01 Million | -0.529x | -137.68% |
| 2015-12-31 | $35.63 Million | $-7.93 Million | -0.222x | +55.64% |
| 2014-12-31 | $9.48 Million | $-4.75 Million | -0.501x | -37.70% |
| 2013-12-31 | $9.30 Million | $-3.38 Million | -0.364x | +44.59% |
| 2012-12-31 | $6.85 Million | $-4.50 Million | -0.657x | +5.12% |
| 2011-12-31 | $7.77 Million | $-5.38 Million | -0.693x | -84.96% |
| 2010-12-31 | $11.51 Million | $-4.31 Million | -0.375x | +80.86% |
| 2009-12-31 | $1.57 Million | $-3.08 Million | -1.957x | -208.82% |
| 2008-12-31 | $-2.10 Million | $-3.78 Million | 1.798x | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency… Read more